{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:24:32Z","timestamp":1788560672985,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"State of Vermont Department of Vermont Health Access","award":["39184"],"award-info":[{"award-number":["39184"]}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA029926"],"award-info":[{"award-number":["P30DA029926"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Opioid-related fatal overdoses are occurring at historically high levels and increasing each year. Accessible social and financial support are imperative to the initiation and success of treatment for Opioid Use Disorder (OUD). Medications for Opioid Use Disorder (MOUD) offer effective treatment but there are many more people with untreated OUD than receiving evidence-based medication. Patient-centered care is associated with increased care utilization for substance use disorders. This qualitative study explored the patient perspective of OUD care through a Patient-Centered Care (PCC) framework to illuminate patients\u2019 sense of engagement in care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Fifteen semi-structured telephone interviews were conducted from August through November of 2021 regarding patient experiences receiving MOUD in 13 Vermont Hub and Spoke clinics. Emergent themes were deductively mapped to PCC domains of Therapeutic Alliance, Individualized Care, Shared Decision-Making, and Holistic Care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Participants indicated that PCC fostered engagement and often characterized MOUD clinics they no longer attended as lacking in PCC. Themes related to Therapeutic Alliance were the most prevalent and suggest pathways to retention. Individualizing care through flexible appointment scheduling was strongly valued, while inflexible scheduling fostered fear of not getting medication. Some participants indicated they were less likely to remain in care when providers did not include them in decisions about medication type, dose, or formulation. Participants also appreciated holistic biopsychosocial care and care referrals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Patient-centered MOUD care was important to participants and encouraged engagement in care. Prioritizing alliance with patients, adapting care to patient needs and preferences particularly when scheduling, including patients in medication decisions, and biopsychosocial attention to patients are congruent with patient perception of desirable MOUD care. Having this understanding of an established, leading MOUD treatment system may serve to benefit states looking to implement this model, or for states who are looking to improve the model they already have in place, potentially leading to higher treatment and retention rates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>This was not a clinical trial involving an intervention, and therefore registration was not required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-024-00529-8","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T04:32:57Z","timestamp":1736829177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient centered medication treatment for opioid use disorder in rural Vermont: a qualitative study"],"prefix":"10.1186","volume":"20","author":[{"given":"Emily G.","family":"Hichborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen B.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilis I.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess E.","family":"Gallant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany M.","family":"McLeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Saroyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Folland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Marsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"529_CR1","unstructured":"CDC - Data Briefs, #457-. December 2022. 2022."},{"key":"529_CR2","doi-asserted-by":"crossref","unstructured":"Merianne RS, Garnett M, Arialdi MM. Urban\u2013rural differences in drug overdose death rates, 2020. National Vital Statistics System Data Brief No. 440. July 2022.","DOI":"10.15620\/cdc:118601"},{"key":"529_CR3","unstructured":"National Academies of Sciences E, Medicine, Health, Medicine D, Board on Health Sciences P. Committee on Medication-Assisted Treatment for Opioid Use D. Medications for Opioid Use Disorder Save Lives. National Academies; 2019. p. 174. 2019\/6\/16."},{"key":"529_CR4","doi-asserted-by":"publisher","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","volume":"110","author":"N Krawczyk","year":"2022","unstructured":"Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerd\u00e1 M. Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"529_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/jrh.12491","volume":"37","author":"WL Swann","year":"2021","unstructured":"Swann WL, Kim S, Kim SY, Schreiber TL. Urban-Rural Disparities in Opioid Use Disorder Prevention and Response Activities: A Cross-Sectional Analysis. J Rural Health. 2021;37(1):16\u201322.","journal-title":"J Rural Health"},{"key":"529_CR6","doi-asserted-by":"publisher","first-page":"109081","DOI":"10.1016\/j.drugalcdep.2021.109081","volume":"228","author":"MV Kiang","year":"2021","unstructured":"Kiang MV, Barnett ML, Wakeman SE, Humphreys K, Tsai AC. Robustness of estimated access to opioid use disorder treatment providers in rural vs. urban areas of the United States. Drug Alcohol Depend. 2021;228:109081.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"529_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","volume":"46","author":"JJ Lister","year":"2020","unstructured":"Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46(3):273\u201388.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"529_CR8","unstructured":"Health VTDo. Fatal Overdoses Among Vermonters - Data Through 2022. 2023."},{"key":"529_CR9","unstructured":"Vermont Department of H. Opioid-Related Fatalities Among Vermonters. 2021."},{"issue":"Pt 2","key":"529_CR10","doi-asserted-by":"publisher","first-page":"106765","DOI":"10.1016\/j.ypmed.2021.106765","volume":"152","author":"VS Harder","year":"2021","unstructured":"Harder VS, Villanti AC, Heil SH, Smith ML, Gaalema DE, Meyer MC, et al. Opioid use disorder treatment in rural settings: The primary care perspective. Prev Med. 2021;152(Pt 2):106765.","journal-title":"Prev Med"},{"issue":"4","key":"529_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","volume":"11","author":"JR Brooklyn","year":"2017","unstructured":"Brooklyn JR, Sigmon SC. Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact. J Addict Med. 2017;11(4):286\u201392.","journal-title":"J Addict Med"},{"issue":"4","key":"529_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2014.2421","volume":"72","author":"SC Sigmon","year":"2015","unstructured":"Sigmon SC. The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry. 2015;72(4):395\u20136.","journal-title":"JAMA Psychiatry"},{"key":"529_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jsat.2019.07.013","volume":"108","author":"GM Miele","year":"2020","unstructured":"Miele GM, Caton L, Freese TE, McGovern M, Darfler K, Antonini VP, et al. Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact. J Subst Abuse Treat. 2020;108:20\u20135.","journal-title":"J Subst Abuse Treat"},{"key":"529_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jsat.2019.08.016","volume":"106","author":"S Kawasaki","year":"2019","unstructured":"Kawasaki S, Francis E, Mills S, Buchberger G, Hogentogler R, Kraschnewski J. Multi-model implementation of evidence-based care in the treatment of opioid use disorder in Pennsylvania. J Subst Abuse Treat. 2019;106:58\u201364.","journal-title":"J Subst Abuse Treat"},{"key":"529_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jsat.2019.07.007","volume":"108","author":"S Reif","year":"2020","unstructured":"Reif S, Brolin MF, Stewart MT, Fuchs TJ, Speaker E, Mazel SB. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders. J Subst Abuse Treat. 2020;108:33\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"529_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1176\/appi.ps.202100343","volume":"73","author":"DE Marcovitz","year":"2022","unstructured":"Marcovitz DE, Pettapiece-Phillips M, Kast KA, White K, Himelhoch H, Audet C. Implementation of a Hub-and-Spoke Partnership for Opioid Use Disorder Treatment in a Medicaid Nonexpansion State. Psychiatr Serv. 2022;73(7):819\u201322.","journal-title":"Psychiatr Serv"},{"key":"529_CR17","unstructured":"Tipton RE. The Hub and Spoke Solution: A Much-Needed Answer to Tennessee\u2019s Opioid Crisis. University of Tennessee, Knoxville; 2020."},{"key":"529_CR18","doi-asserted-by":"publisher","unstructured":"Heavey SC, Beehler GP, Funderburk J. (RE-)AIMing for rapid uptake: pilot evaluation of a modified hub and spoke model of medication for opioid use disorder. Med Care. 2024;62(1):44\u201351. https:\/\/doi.org\/10.1097\/MLR.0000000000001934. Epub 2023 Oct 6. PMID: 37800974.","DOI":"10.1097\/MLR.0000000000001934"},{"issue":"1","key":"529_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13011-019-0227-0","volume":"14","author":"K Marchand","year":"2019","unstructured":"Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;14(1):37.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"529_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/08897077.2019.1671940","volume":"41","author":"EL Davis","year":"2020","unstructured":"Davis EL, Kelly PJ, Deane FP, Baker AL, Buckingham M, Degan T, et al. The relationship between patient-centered care and outcomes in specialist drug and alcohol treatment: A systematic literature review. Subst Abus. 2020;41(2):216\u201331.","journal-title":"Subst Abus"},{"key":"529_CR21","doi-asserted-by":"publisher","first-page":"108125","DOI":"10.1016\/j.jsat.2020.108125","volume":"118","author":"SE Park","year":"2020","unstructured":"Park SE, Mosley JE, Grogan CM, Pollack HA, Humphreys K, D\u2019Aunno T, et al. Patient-centered care\u2019s relationship with substance use disorder treatment utilization. J Subst Abuse Treat. 2020;118:108125.","journal-title":"J Subst Abuse Treat"},{"key":"529_CR22","doi-asserted-by":"publisher","first-page":"105785","DOI":"10.1016\/j.ypmed.2019.105785","volume":"128","author":"RA Rawson","year":"2019","unstructured":"Rawson RA, Rieckmann T, Cousins S, McCann M, Pearce R. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system. Prev Med. 2019;128:105785.","journal-title":"Prev Med"},{"key":"529_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2019.07.014","volume":"108","author":"K Darfler","year":"2020","unstructured":"Darfler K, Sandoval J, Pearce Antonini V, Urada D. Preliminary results of the evaluation of the California Hub and Spoke Program. J Subst Abuse Treat. 2020;108:26\u201332.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"529_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How Many Interviews Are Enough? An Experiment with Data Saturation and Variability. Field methods. 2006;18(1):59\u201382.","journal-title":"Field methods"},{"key":"529_CR25","unstructured":"ATLAS.Ti. v8.4 ed."},{"issue":"9","key":"529_CR26","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"H-F Hsieh","year":"2005","unstructured":"Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388.","journal-title":"Qual Health Res"},{"issue":"1","key":"529_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1744987117741667","volume":"23","author":"A Assarroudi","year":"2018","unstructured":"Assarroudi A, Heshmati Nabavi F, Armat MR, Ebadi A, Vaismoradi M. Directed qualitative content analysis: the description and elaboration of its underpinning methods and data analysis process. J Res Nurs. 2018;23(1):42\u201355.","journal-title":"J Res Nurs"},{"key":"529_CR28","unstructured":"HRSA. Defining rural population. Available from: https:\/\/www.hrsa.gov\/rural-health\/about-us\/what-is-rural"},{"issue":"8","key":"529_CR29","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.cpr.2013.07.007","volume":"33","author":"HH Brorson","year":"2013","unstructured":"Brorson HH, Ajo Arnevik E, Rand-Hendriksen K, Duckert F. Drop-out from addiction treatment: a systematic review of risk factors. Clin Psychol Rev. 2013;33(8):1010\u201324.","journal-title":"Clin Psychol Rev"},{"issue":"6","key":"529_CR30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3109\/10826084.2012.659789","volume":"47","author":"LM Ruglass","year":"2012","unstructured":"Ruglass LM, Miele GM, Hien DA, Campbell ANC, Hu M-C, Caldeira N, et al. Helping alliance, retention, and treatment outcomes: a secondary analysis from the NIDA Clinical Trials Network Women and Trauma Study. Subst Use Misuse. 2012;47(6):695\u2013707.","journal-title":"Subst Use Misuse"},{"key":"529_CR31","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"key":"529_CR32","doi-asserted-by":"publisher","unstructured":"Austin EJ, O'Brien QE, Ruiz MS, Ratzliff AD, Williams EC, Koch U. Patient and provider perspectives on processes of engagement in outpatient treatment for opioid use disorder: a scoping review. Community Ment Health J. 2024;60(2):330\u2013339. https:\/\/doi.org\/10.1007\/s10597-023-01175-1. Epub 2023 Sep 5. PMID: 37668745.","DOI":"10.1007\/s10597-023-01175-1"},{"issue":"12","key":"529_CR33","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1111\/add.15959","volume":"117","author":"M Burns","year":"2022","unstructured":"Burns M, Tang L, Chang C-CH, Kim JY, Ahrens K, Allen L, et al. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study. Addiction. 2022;117(12):3079\u201388.","journal-title":"Addiction"},{"key":"529_CR34","doi-asserted-by":"publisher","first-page":"108449","DOI":"10.1016\/j.jsat.2021.108449","volume":"131","author":"S Brothers","year":"2021","unstructured":"Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. J Subst Abuse Treat. 2021;131:108449.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"529_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/08897077.2021.1967836","volume":"43","author":"B Chan","year":"2022","unstructured":"Chan B, Bougatsos C, Priest KC, McCarty D, Grusing S, Chou R. Opioid treatment programs, telemedicine and COVID-19: A scoping review. Subst Abus. 2022;43(1):539\u201346.","journal-title":"Subst Abus"},{"issue":"10","key":"529_CR36","doi-asserted-by":"publisher","first-page":"e2336914","DOI":"10.1001\/jamanetworkopen.2023.36914","volume":"6","author":"LR Hammerslag","year":"2023","unstructured":"Hammerslag LR, Mack A, Chandler RK, Fanucchi LC, Feaster DJ, LaRochelle MR, et al. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees. JAMA Netw Open. 2023;6(10):e2336914.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"529_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1037\/rmh0000206","volume":"46","author":"J Kaur","year":"2022","unstructured":"Kaur J, Mania I, Tirupathi R, Polavarapu L. Impact of telemedicine on retention in Medications for Opioid Use Disorder (MOUD) treatment with buprenorphine in the times of COVID-19 pandemic: A retrospective chart review. J Rural Mental Health. 2022;46(2):75\u201381.","journal-title":"J Rural Mental Health"},{"key":"529_CR38","doi-asserted-by":"publisher","first-page":"108633","DOI":"10.1016\/j.jsat.2021.108633","volume":"132","author":"N Beharie","year":"2022","unstructured":"Beharie N, Kaplan-Dobbs M, Urmanche A, Paone D, Harocopos A. I didn\u2019t feel like a number: The impact of nurse care managers on the provision of buprenorphine treatment in primary care settings. J Subst Abuse Treat. 2022;132:108633.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"529_CR39","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1080\/08897077.2021.1904091","volume":"42","author":"E Peacock-Chambers","year":"2021","unstructured":"Peacock-Chambers E, Paterno MT, Kiely D, Fioroni T, Byatt N, Friedmann PD. Engagement in perinatal outpatient services among women in recovery from opioid use disorders. Subst Abus. 2021;42(4):1022\u20139.","journal-title":"Subst Abus"},{"issue":"4","key":"529_CR40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00132576-200211000-00001","volume":"1","author":"JL Pringle","year":"2002","unstructured":"Pringle JL, Edmondston LA, Holland CL, Kirisci L, Emptage NP, Balavage VK, et al. The Role of Wrap Around Services in Retention and Outcome in Substance Abuse Treatment: Findings From the Wrap Around Services Impact Study. Addict Disord Their Treat. 2002;1(4):109.","journal-title":"Addict Disord Their Treat"},{"issue":"4","key":"529_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","volume":"71","author":"SC Sigmon","year":"2014","unstructured":"Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry. 2014;71(4):359\u201360.","journal-title":"JAMA Psychiatry"},{"key":"529_CR42","doi-asserted-by":"publisher","first-page":"116660","DOI":"10.1016\/j.socscimed.2024.116660","volume":"346","author":"TJ Stopka","year":"2024","unstructured":"Stopka TJ, Estadt AT, Leichtling G, Schleicher JC, Mixson LS, Bresett J, et al. Barriers to opioid use disorder treatment among people who use drugs in the rural United States: A qualitative, multi-site study. Soc Sci Med. 2024;346:116660.","journal-title":"Soc Sci Med"},{"issue":"2","key":"529_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/1073110518782951","volume":"46","author":"Q Johnson","year":"2018","unstructured":"Johnson Q, Mund B, Joudrey PJ. Improving Rural Access to Opioid Treatment Programs. J Law Med Ethics. 2018;46(2):437\u20139.","journal-title":"J Law Med Ethics"},{"issue":"1","key":"529_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jrh.12488","volume":"38","author":"MM Ali","year":"2022","unstructured":"Ali MM, Nye E, West K. Substance Use Disorder Treatment, Perceived Need for Treatment, and Barriers to Treatment Among Parenting Women With Substance Use Disorder in US Rural Counties. J Rural Health. 2022;38(1):70\u20136.","journal-title":"J Rural Health"},{"issue":"1","key":"529_CR45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13722-023-00417-7","volume":"18","author":"SG Mitchell","year":"2023","unstructured":"Mitchell SG, Jester J, Gryczynski J, Whitter M, Fuller D, Halsted C, et al. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff. Addict Sci Clin Pract. 2023;18(1):61.","journal-title":"Addict Sci Clin Pract"},{"key":"529_CR46","doi-asserted-by":"publisher","first-page":"108008","DOI":"10.1016\/j.jsat.2020.108008","volume":"115","author":"JR Jackson","year":"2020","unstructured":"Jackson JR, Harle CA, Silverman RD, Simon K, Menachemi N. Characterizing variability in state-level regulations governing opioid treatment programs. J Subst Abuse Treat. 2020;115:108008.","journal-title":"J Subst Abuse Treat"},{"key":"529_CR47","doi-asserted-by":"publisher","first-page":"111067","DOI":"10.1016\/j.drugalcdep.2023.111067","volume":"255","author":"PS Michener","year":"2024","unstructured":"Michener PS, Knee A, Wilson D, Boama-Nyarko E, Friedmann PD. Association of random and observed urine drug screening with long-term retention in opioid treatment programs. Drug Alcohol Depend. 2024;255:111067.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"529_CR48","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3109\/14659890903431603","volume":"15","author":"C Strike","year":"2010","unstructured":"Strike C, Rufo C. Embarrassing, degrading, or beneficial: Patient and staff perspectives on urine drug testing in methadone maintenance treatment. J Subst Use. 2010;15(5):303\u201312.","journal-title":"J Subst Use"},{"issue":"4","key":"529_CR49","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/cpp.2062","volume":"24","author":"SM Gainsbury","year":"2017","unstructured":"Gainsbury SM. Cultural Competence in the Treatment of Addictions: Theory, Practice and Evidence. Clin Psychol Psychother. 2017;24(4):987\u20131001.","journal-title":"Clin Psychol Psychother"},{"key":"529_CR50","unstructured":"United States Census Bureau. QuickFacts: Vermont. 2023. https:\/\/www.census.gov\/quickfacts\/VT. Accessed 30 Oct 2023."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00529-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00529-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00529-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T04:33:06Z","timestamp":1736829186000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00529-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["529"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00529-8","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"10 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Dartmouth College Committee for the Protection of Human Subjects Institutional Review Board. Consent procedures included a verbal consent to conduct and record the interview.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"EGH conducted this research study, data cleaning, analyses, and manuscript writing while at Dartmouth College.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Information"}}],"article-number":"3"}}